Company news

Gentian Diagnostics ASA news in 2026

Gentian Diagnostics ASA's news releases, calls and decks from 2026, newest first.

View company

Second quarter 2026 report

July 9, 2026

Gentian Diagnostics - Second quarter 2026 report

July 9, 2026

Essange Reagents And Gentian Diagnostics Announce Collaboration Agreement

June 24, 2026

Join our R&D Team in Gothenburg

May 28, 2026

Gentian Diagnostics: Vatne Capital Reduces Indirect Ownership

May 13, 2026

Serum calprotectin - marker of systemic inflammation and disease activity

May 12, 2026

GENT: Q1 saw stable sales, NT-proBNP project termination, and a focus on new growth opportunities

May 6, 2026

Gentian Diagnostics: Invitation to presentation of first quarter results

April 29, 2026

Gentian Diagnostics Renews Long-Term Partnership With Bühlmann Laboratories

April 20, 2026

Gentian Diagnostics ASA - Registration of share capital increase

April 10, 2026

Calprotectin as a biomarker for immune dysfunction and 28‑day mortality in sepsis

March 26, 2026

Gentian Diagnostics: Annual report 2025

March 20, 2026

Mandatory notification of trade

February 12, 2026

GENT: Record 2025 sales, strong US growth, new partnership, and NT-proBNP development setback

February 11, 2026

Gentian Diagnostics: Invitation to presentation of fourth quarter results

February 4, 2026

Gentian Diagnostics invites to NT-proBNP educational webinar

January 28, 2026

Gentian Diagnostics Enters Exclusive Agreement With Global Diagnostics Company

January 7, 2026

Decks in 2026